Self-screening questionnaire for perianal fistulizing disease in patients with Crohn’s disease
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: A poor prognostic factor for Crohn’s disease (CD) includes perianal fistulizing disease, including perianal fistula and/or perianal abscess. Currently, a tool to assess perianal symptoms in patients with CD remains nonexistent. This study aimed to develop a perianal fistulizing disease self-screening questionnaire for patients with CD. Methods: This prospective pilot study was conducted at three tertiary referral centers between January 2019 and May 2020. We formulated questions on perianal symptoms, including tenesmus, anal discharge, bleeding, pain, and heat. A 4-point Likert scale was used to rate each question. Patients with CD completed a questionnaire and underwent pelvic magnetic resonance imaging (MRI). Results: Overall, 93 patients were enrolled, with 51 (54.8%) diagnosed with perianal fistulizing disease, as determined by pelvic MRI. The Spearman correlation findings demonstrated that anal pain (p = 0.450, p < 0.001) and anal discharge (p = 0.556, p < 0.001) were the symptoms that most significantly correlated with perianal disease. For anal pain and discharge, the area under the receiver operating characteristic curve of the scores was significantly higher than that of the combined score for all five symptoms (0.855 vs. 0.794, DeLong’s test p = 0.04). For the two symptoms combined, the sensitivity, specificity, and positive predictive and negative predictive values were 88.2, 73.8, 80.4, and 83.8%, respectively, with 81.7% accuracy for detecting perianal fistulizing disease. Conclusions: This study indicates that simple questions regarding anal pain and discharge can help accurately identify the presence of perianal fistulizing disease in patients with CD.
Abstract
Background/Aims: A poor prognostic factor for Crohn’s disease (CD) includes perianal fistulizing disease, including perianal fistula and/or perianal abscess. Currently, a tool to assess perianal symptoms in patients with CD remains nonexistent. This study aimed to develop a perianal fistulizing disease self-screening questionnaire for patients with CD. Methods: This prospective pilot study was conducted at three tertiary referral centers between January 2019 and May 2020. We formulated questions on perianal symptoms, including tenesmus, anal discharge, bleeding, pain, and heat. A 4-point Likert scale was used to rate each question. Patients with CD completed a questionnaire and underwent pelvic magnetic resonance imaging (MRI). Results: Overall, 93 patients were enrolled, with 51 (54.8%) diagnosed with perianal fistulizing disease, as determined by pelvic MRI. The Spearman correlation findings demonstrated that anal pain (p = 0.450, p < 0.001) and anal discharge (p = 0.556, p < 0.001) were the symptoms that most significantly correlated with perianal disease. For anal pain and discharge, the area under the receiver operating characteristic curve of the scores was significantly higher than that of the combined score for all five symptoms (0.855 vs. 0.794, DeLong’s test p = 0.04). For the two symptoms combined, the sensitivity, specificity, and positive predictive and negative predictive values were 88.2, 73.8, 80.4, and 83.8%, respectively, with 81.7% accuracy for detecting perianal fistulizing disease. Conclusions: This study indicates that simple questions regarding anal pain and discharge can help accurately identify the presence of perianal fistulizing disease in patients with CD.
참고문헌 (28)
- Wewer MD, "The incidence and disease course of perianal Crohn’s disease : a Danish nationwide cohort study, 1997-2015", J Crohns Colitis, 15, pp.5~13 (2021)
- Gajendran M, "A comprehensive review and update on Crohn’s disease", Dis Mon, 64, pp.20~57 (2018)
- Shi HY, "Ethnicity influences phenotype and outcomes in inflammatory bowel disease : a systematic review and meta-analysis of population-based studies", Clin Gastroenterol Hepatol, 16, pp.190~197 (2018)
- Kaur M, "Inpatient management of inflammatory bowel disease-related complications", Clin Gastroenterol Hepatol, 18, pp.1346~1355 (2020)
- Adegbola SO, "Burden of disease and adaptation to life in patients with Crohn’s perianal fistula : a qualitative exploration", Health Qual Life Outcomes, 18, pp.370~ (2020)
- Present DH, "Infliximab for the treatment of fistulas in patients with Crohn’s disease", N Engl J Med, 340, pp.1398~1405 (1999)
- Lichtiger S, "The CHOICE trial : adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy", Aliment Pharmacol Ther, 32, pp.1228~1239 (2010)
- Panés J, "Perianal fistulizing Crohn’s disease : pathogenesis, diagnosis and therapy", Nat Rev Gastroenterol Hepatol, 14, pp.652~664 (2017)
- Meima-van Praag EM, "Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn’s disease(PISA-II) : a patient preference randomised trial", Lancet Gastroenterol Hepatol, 7, pp.617~626 (2022)
- Badla O, "The multidisciplinary management of perianal fistulas in Crohn’s disease : a systematic review", Cureus, 14, pp.e29347~ (2022)
- Laland M, "Identification of the optimal medical and surgical management for patients with perianal fistulising Crohn’s disease", Colorectal Dis, 25, pp.75~82 (2023)
- Ye BD, "Diagnostic guideline of Crohn’s disease", Korean J Gastroenterol, 53, pp.161~176 (2009)
- Koh SJ, "Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease", Intest Res, 21, pp.43~60 (2023)
- Satsangi J, "The Montreal classification of inflammatory bowel disease : controversies, consensus, and implications", Gut, 55, pp.749~753 (2006)
- Harvey RF, "A simple index of Crohn’s-disease activity", Lancet, 1, pp.514~ (1980)
- Panes J, "Imaging techniques for assessment of inflammatory bowel disease : joint ECCO and ESGAR evidence-based consensus guidelines", J Crohns Colitis, 7, pp.556~585 (2013)
- Steinhart AH, "Clinical practice guideline for the medical management of perianal fistulizing Crohn’s disease : the Toronto consensus", Inflamm Bowel Dis, 25, pp.1~13 (2019)
- Juncadella AC, "Perianal Crohn’s disease : a review", Postgrad Med, 127, pp.266~272 (2015)
- Schober P, "Correlation coefficients : appropriate use and interpretation", Anesth Analg, 126, pp.1763~1768 (2018)
- Atia O, "Perianal Crohn disease is more common in children and is associated with complicated disease course despite higher utilization of biologics : a population-based study from the epidemiology group of the Israeli IBD Research Nucleus(epiIIRN)", J Pediatr Gastroenterol Nutr, 74, pp.788~793 (2022)
- Allan A, "Clinical index to quantitate symptoms of perianal Crohn’s disease", Dis Colon Rectum, 35, pp.656~661 (1992)
- Irvine EJ, "Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD Study Group", J Clin Gastroenterol, 20, pp.27~32 (1995)
- Pikarsky AJ, "Perianal Crohn disease : a new scoring system to evaluate and predict outcome of surgical intervention", Arch Surg, 137, pp.774~777 (2002)
- Schwartz DA, "The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota", Gastroenterology, 122, pp.875~880 (2002)
- : clinical aspects of perianal fistulising Crohn’s disease-the unmet needs, "J Crohns Colitis", 2016, 758~765
- García-Olmo D, "A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation", Dis Colon Rectum, 48, pp.1416~1423 (2005)
- Barreiro Domínguez EM, "Mesenchymal stem cells for the treatment of perianal fistulizing Crohn’s disease-a video vignette", Colorectal Dis, 24, pp.1441~1442 (2022)
- Tanaka S, "Clinical advantages of combined seton placement and infliximab maintenance therapy for perianal fistulizing Crohn’s disease : when and how were the seton drains removed?", Hepatogastroenterology, 57, pp.3~7 (2010)